Cytek Biosciences, Inc.

The momentum for this stock is not very good. Cytek Biosciences, Inc. is not very popular among insiders. Cytek Biosciences, Inc. is a mediocre stock to choose.

News

Cytek Announces Resignation of Chief Operating Officer Chris Williams

Globe Newswire FREMONT, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced that its Chief Operating Officer, Chris...\n more…

Principal Financial Group Inc. Sells 38,550 Shares of Cytek Biosciences, Inc. (NASDAQ:CTKB)

Ticker Report Principal Financial Group Inc. lowered its position in Cytek Biosciences, Inc. (NASDAQ:CTKB - Free Report) by 7.4% during the 2nd quarter, according to the company in its most recent Form 13F filing...\n more…

Cytek Biosciences, Inc. (NASDAQ:CTKB) Shares Sold by Versor Investments LP

Zolmax Versor Investments LP reduced its stake in shares of Cytek Biosciences, Inc. (NASDAQ:CTKB - Free Report) by 52.2% during the 2nd quarter, Holdings Channel.com reports. The fund owned 22,400 shares...\n more…

Piper Sandler Reaffirms Their Buy Rating on Cytek Biosciences (CTKB)

TipRanks Financial Blog Piper Sandler analyst David Westenberg maintained a Buy rating on Cytek Biosciences (CTKB - Research Report) today and set a price target of $8.00....\n more…

12,500 Shares in Cytek Biosciences, Inc. (NASDAQ:CTKB) Purchased by SlateStone Wealth LLC

Zolmax SlateStone Wealth LLC purchased a new stake in shares of Cytek Biosciences, Inc. (NASDAQ:CTKB - Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC...\n more…

Cytek Biosciences Achieves ISO 13485 Certification at San Diego Reagent Manufacturing Facility

Globe Newswire Certification Emphasizes Unwavering Commitment to Quality and Is an Essential Step for U.S. Clinical Market EntryFREMONT, Calif., Aug. 21, 2024 (GLOBE NEWSWIRE) -- Today Cytek Biosciences, Inc...\n more…